Technical Data
T9160-15R
Tumor Necrosis Factor alpha, Recombinant, Human (TNF-alpha, TNFA, TNF-a, Cachectin, DIF, Tumor Necrosis Factor, TNF, Tumor Necrosis Factor Ligand Superfamily Member 2, TNFSF2)
10ug
Molecular Biology Storage: -20CShipping: Blue Ice
Source:
Recombinant corresponding to 158aa of human Tumor Necrosis Factor-alpha expressed in E.coli is a single, non-glycosylated, polypeptide chain.

Molecular Weight:
~17.5kD

Biological Activity:
The ED50 as determined by the cytolysis of mouse L929 cells in the presence of Actinomycin D is less then 0.05ng/ml, corresponding to a Specific Activity of 2x107IU/mg.

Dimers and Aggregates:
1% (SDS-PAGE)

Protein Content:
Protein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280nm using the absorbency value of 1.24 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a calibrated solution of TNF-alpha as a Reference Standard.

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile ddH2O, HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Molecular Weight:
~17.5kD
Purity: ~98% (RP-HPLC, Anion-exchange FPLC, SDS-PAGE) Endotoxin: 0.1ng/ug (IEU/ug)
Concentration: Not determined
Form: Supplied as a lyophilized powder. No preservative added. Reconstitute with sterile dH2O, 0.1% HSA or BSA to 0.1mg/ml.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Translational research on TNF-alpha as an endogenous tumor promoter and green tea as cancer preventive in humans. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2005;23(1):3-30. 2. Small-molecule inhibition of TNF-alpha. Science 2005 Nov 11;310(5750):1022-5. 3. Release of TNF-alpha and IL-1beta from porcine brain endothelium corresponds to the pyrogenic potential of three marketed formulations of amphotericin. Inflamm Res 2005 Sep;54(9):375-9. 4. Roles of TNF-alpha and IgE in the late phase of contact hypersensitivity induced by trimellitic anhydride. Exp Mol Med 2005 Oct 31;37(5):408-17. 5. Cellular cIAP2 gene expression associated with anti-HBV activity of TNF-alpha in hepatoblastoma cells. J Interferon Cytokine Res 2005 Oct;25(10):617-26. 6. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) block ing agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 2005 Nov;64 Suppl 4:iv2-14.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.